Nutrigenomics Market Size, Share & Trends Analysis Report By Application (Obesity, Cardiovascular Diseases, Cancer Research), By Product, By Technique, By End Use, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 2 Business Days
NUT Midline Carcinoma Treatment Market Growth & Trends
The global NUT midline carcinoma treatment market size is anticipated to reach USD 44.1 billion by 2030, growing at a CAGR of 12.4%, according to a report by Grand View Research, Inc. This significant growth is majorly driven by the increasing awareness of rare cancer types, advancements in targeted therapies, and the growing focus on precision medicine. With advancements in diagnostic tools and greater awareness among healthcare professionals, more cases are being identified earlier, leading to an increased demand for effective treatments.
The rise of targeted therapies, particularly those focusing on epigenetic mechanisms, has been pivotal in this market. For instance, the development of BET (bromodomain and extra-terminal) inhibitors, which target the BRD4-NUT fusion protein commonly associated with NMC, has opened new avenues for treatment. Companies such as Bristol-Myers Squibb are at the forefront of this research, developing drugs such as Trotabresib (CC-90010), which are currently in clinical trials. The aggressive nature of the disease and the poor prognosis associated with it create a strong imperative for the development of new therapies. The rarity of the disease also presents challenges, including limited patient pools for clinical trials and a lack of comprehensive epidemiological data.
Government and regulatory bodies are also playing a crucial role in accelerating the development of NMC treatments. In many regions, including the U.S. and Europe, NMC has been granted orphan disease status, providing incentives such as tax credits and extended market exclusivity to companies developing treatments for this rare cancer. These incentives are critical in encouraging investment in NMC research, which is otherwise limited due to the small patient population.
NUT Midline Carcinoma Treatment Market Report Highlights
NUT Midline Carcinoma Treatment Market Growth & Trends
The global NUT midline carcinoma treatment market size is anticipated to reach USD 44.1 billion by 2030, growing at a CAGR of 12.4%, according to a report by Grand View Research, Inc. This significant growth is majorly driven by the increasing awareness of rare cancer types, advancements in targeted therapies, and the growing focus on precision medicine. With advancements in diagnostic tools and greater awareness among healthcare professionals, more cases are being identified earlier, leading to an increased demand for effective treatments.
The rise of targeted therapies, particularly those focusing on epigenetic mechanisms, has been pivotal in this market. For instance, the development of BET (bromodomain and extra-terminal) inhibitors, which target the BRD4-NUT fusion protein commonly associated with NMC, has opened new avenues for treatment. Companies such as Bristol-Myers Squibb are at the forefront of this research, developing drugs such as Trotabresib (CC-90010), which are currently in clinical trials. The aggressive nature of the disease and the poor prognosis associated with it create a strong imperative for the development of new therapies. The rarity of the disease also presents challenges, including limited patient pools for clinical trials and a lack of comprehensive epidemiological data.
Government and regulatory bodies are also playing a crucial role in accelerating the development of NMC treatments. In many regions, including the U.S. and Europe, NMC has been granted orphan disease status, providing incentives such as tax credits and extended market exclusivity to companies developing treatments for this rare cancer. These incentives are critical in encouraging investment in NMC research, which is otherwise limited due to the small patient population.
NUT Midline Carcinoma Treatment Market Report Highlights
- In 2023, the chemotherapy segment accounted for the largest revenue share of 32.5% in NUT midline carcinoma treatment market.
- The intravenous segment accounts for the largest revenue share of 68.7% in 2023 driven by the need for fast-acting treatments in managing NMC due to its higher bioavailability and quicker delivery of the drug to the bloodstream, ensuring that the potent therapies reach the tumor cells more effectively than oral medications might.
- Specialty clinics are anticipated to achieve the highest CAGR of 13.5% during the forecast period.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. NUTRIGENOMICS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Nutrigenomics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. NUTRIGENOMICS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Nutrigenomics Market: Application Movement Analysis, 2023 & 2030 (USD Million)
4.3. Obesity
4.3.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Cardiovascular Diseases
4.4.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Cancer Research
4.5.1. Cancer Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Others
4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. NUTRIGENOMICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Nutrigenomics Market: Product Movement Analysis, 2023 & 2030 (USD Million)
5.3. Reagents & Kits
5.3.1. Reagents &Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Services
5.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. NUTRIGENOMICS MARKET: TECHNIQUE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Nutrigenomics Market: Technique Movement Analysis, 2023 & 2030 (USD Million)
6.3. Saliva
6.3.1. Saliva Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Buccal Swab
6.4.1. Buccal Swab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Blood
6.5.1. Blood Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. NUTRIGENOMICS MARKET: END USE ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Nutrigenomics Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
7.3. Hospitals & Clinics
7.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Others
7.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. NUTRIGENOMICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
8.1. Nutrigenomics Market Share, By Region, 2023 & 2030 (USD Million)
8.2. North America
8.2.1. North America Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. U.S. Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Canada Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.4. Mexico
8.2.4.1. Mexico Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. Europe Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.2. UK
8.3.2.1. UK Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Germany Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.4. France
8.3.4.1. France Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Italy Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Spain Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Denmark Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Sweden Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.9. Norway
8.3.9.1. Norway Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.2. China
8.4.2.1. China Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Japan Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.4. India
8.4.4.1. India Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.5. South Korea
8.4.5.1. South Korea Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.6. Australia
8.4.6.1. Australia Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Thailand Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Brazil Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.3. Argentina
8.5.3.1. Argentina Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Middle East and Africa
8.6.1. Middle East and Africa Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. South Africa Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Saudi Arabia Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.4. UAE
8.6.4.1. UAE Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Kuwait Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Heat Map Analysis
9.4. Company Profiles
9.4.1. Nutrigenomix
9.4.1.1. Participant’s Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Recent Developments/Strategic Initiatives
9.4.2. The Gene Box
9.4.2.1. Participant’s Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Recent Developments/Strategic Initiatives
9.4.3. Metagenics
9.4.3.1. Participant’s Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Recent Developments/Strategic Initiatives
9.4.4. Xcode Life
9.4.4.1. Participant’s Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Recent Developments/Strategic Initiatives
9.4.5. GX Sciences, LLC (Fagron)
9.4.5.1. Participant’s Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Recent Developments/Strategic Initiatives
9.4.6. Cura Integrative Medicine
9.4.6.1. Participant’s Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Recent Developments/Strategic Initiatives
9.4.7. dnalife
9.4.7.1. Participant’s Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Recent Developments/Strategic Initiatives
9.4.8. Genova Diagnostics (GDX)
9.4.8.1. Participant’s Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Recent Developments/Strategic Initiatives
9.4.9. HOLISTIC HEALTH INTERNATIONAL, LLC
9.4.9.1. Participant’s Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Recent Developments/Strategic Initiatives
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. NUTRIGENOMICS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Nutrigenomics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. NUTRIGENOMICS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Nutrigenomics Market: Application Movement Analysis, 2023 & 2030 (USD Million)
4.3. Obesity
4.3.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Cardiovascular Diseases
4.4.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Cancer Research
4.5.1. Cancer Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Others
4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. NUTRIGENOMICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Nutrigenomics Market: Product Movement Analysis, 2023 & 2030 (USD Million)
5.3. Reagents & Kits
5.3.1. Reagents &Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Services
5.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. NUTRIGENOMICS MARKET: TECHNIQUE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Nutrigenomics Market: Technique Movement Analysis, 2023 & 2030 (USD Million)
6.3. Saliva
6.3.1. Saliva Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Buccal Swab
6.4.1. Buccal Swab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Blood
6.5.1. Blood Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. NUTRIGENOMICS MARKET: END USE ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Nutrigenomics Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
7.3. Hospitals & Clinics
7.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Others
7.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. NUTRIGENOMICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
8.1. Nutrigenomics Market Share, By Region, 2023 & 2030 (USD Million)
8.2. North America
8.2.1. North America Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. U.S. Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Canada Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.4. Mexico
8.2.4.1. Mexico Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. Europe Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.2. UK
8.3.2.1. UK Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Germany Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.4. France
8.3.4.1. France Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Italy Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Spain Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Denmark Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Sweden Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.9. Norway
8.3.9.1. Norway Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.2. China
8.4.2.1. China Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Japan Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.4. India
8.4.4.1. India Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.5. South Korea
8.4.5.1. South Korea Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.6. Australia
8.4.6.1. Australia Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Thailand Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Brazil Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.3. Argentina
8.5.3.1. Argentina Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Middle East and Africa
8.6.1. Middle East and Africa Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. South Africa Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Saudi Arabia Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.4. UAE
8.6.4.1. UAE Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Kuwait Nutrigenomics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Heat Map Analysis
9.4. Company Profiles
9.4.1. Nutrigenomix
9.4.1.1. Participant’s Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Recent Developments/Strategic Initiatives
9.4.2. The Gene Box
9.4.2.1. Participant’s Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Recent Developments/Strategic Initiatives
9.4.3. Metagenics
9.4.3.1. Participant’s Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Recent Developments/Strategic Initiatives
9.4.4. Xcode Life
9.4.4.1. Participant’s Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Recent Developments/Strategic Initiatives
9.4.5. GX Sciences, LLC (Fagron)
9.4.5.1. Participant’s Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Recent Developments/Strategic Initiatives
9.4.6. Cura Integrative Medicine
9.4.6.1. Participant’s Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Recent Developments/Strategic Initiatives
9.4.7. dnalife
9.4.7.1. Participant’s Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Recent Developments/Strategic Initiatives
9.4.8. Genova Diagnostics (GDX)
9.4.8.1. Participant’s Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Recent Developments/Strategic Initiatives
9.4.9. HOLISTIC HEALTH INTERNATIONAL, LLC
9.4.9.1. Participant’s Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Recent Developments/Strategic Initiatives
